The Business Research Company’s report on the Intravenous Iron Drugs Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the intravenous iron drugs market?
The growing incidence of chronic kidney disease (CKD) is expected to propel the growth of the intravenous iron drugs market going forward. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time, leading to the kidneys’ inability to effectively filter waste and excess fluids from the blood. The growing incidence of chronic kidney disease (CKD) is due to increasing rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs help chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, which enhances oxygen transport and reduces the need for erythropoiesis-stimulating agents. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates rose by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD was responsible for about 22,000 deaths in Australia, making up 11% of all fatalities. Therefore, the growing incidence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs market.
Access Your Free Sample of the Global Intravenous Iron Drugs Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp
How has the intravenous iron drugs market size evolved, and what are the latest forecasts for its expansion?
The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.44 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing prevalence of iron deficiency anemia, rising prevalence of chronic diseases, increasing healthcare spending, aging population, and rising incidence of target illnesses.
The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $5.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to government initiatives, research and development in the field of IV iron drugs, increasing demand for intravenous iron medicines, increasing number of research and development activities, and improvement in administration and formulation. Major trends in the forecast period include advanced intravenous iron therapies, advancements in drug development, shift towards more convenient iv iron therapies, strategic collaborations partnerships and acquisitions, and innovations in novel drug delivery systems.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp
Which major companies dominate the intravenous iron drugs market?
Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation
What key trends are expected to drive the intravenous (iv) ibuprofen market during the forecast period?
Major companies operating in the intravenous iron drugs market are focusing on developing innovative therapies, such as intravenous (IV) iron replacement therapy, to improve efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical treatment that delivers iron directly into the bloodstream through an intravenous infusion. This therapy treats iron deficiency and anemia, especially in patients who cannot tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company that specializes in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to enhance exercise capacity. Injectafer is a widely used intravenous iron therapy known for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.
Which region dominates the intravenous iron drugs market, and what factors contribute to its leadership?
North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report
How is the intravenous iron drugs market segmented, and which segment holds the largest share?
The intravenous iron drugs market covered in this report is segmented –
1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430
What defines the structure and scope of the intravenous iron drugs market?
Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
